FUROSEMIDE
| Brand name | FUROSCIX READYFLOW (AUTOINJECTOR) |
|---|---|
| Active ingredient | FUROSEMIDE |
| Strength | 80MG/ML (80MG/ML) |
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Modality | Small molecule |
| FDA approval | July 2026 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 12491197 | January 2040 | product |
| 12491196 | January 2040 | product |
| 12491195 | January 2040 | product |
| 12491194 | January 2040 | product |
| 12491193 | January 2040 | product |
| 12048709 | January 2040 | product |
| 11998555 | January 2040 | product |
| 11559535 | January 2040 | product |
| 11571434 | January 2040 | product |
| 11497755 | January 2040 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.